SCHEMBL4686356

SCHEMBL4686356

COc1cc(I)ccc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.43
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 3/20 0.43
MAPT P10636 2/20 0.43
DYRK1A Q13627 1/20 0.43
L3MBTL1 Q9Y468 3/20 0.42
MAPK1 P28482 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
USP2 O75604 1/20 0.42
POLB P06746 1/20 0.42
CYP2C9 P11712 1/20 0.42
HPGD P15428 1/20 0.42
ALOX12 P18054 1/20 0.42
CYP2C19 P33261 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
TSHR P16473 1/20 0.41
MCOLN3 Q8TDD5 1/20 0.41
FFAR4 Q5NUL3 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1476958 0.82 GAA (0.43) GAANPC1ALDH1A1MAPTL3MBTL1
SCHEMBL28075653 0.79 TP53 (0.48) ALDH1A1MAPTL3MBTL1MAPK1MEN1
SCHEMBL470124 0.78 CA2 (0.54) ALDH1A1MAPK1POLBCYP2C9CYP2C19
SCHEMBL31277237 0.78 CA2 (0.54) ALDH1A1MAPK1POLBCYP2C9CYP2C19
SCHEMBL13860477 0.77 HTR2A (0.54)
SCHEMBL28089646 0.77 L3MBTL1 (0.50) NPC1ALDH1A1MAPTL3MBTL1MAPK1
SCHEMBL4302847 0.76 DYRK1A (0.65) GAANPC1ALDH1A1MAPTDYRK1A
SCHEMBL197234 0.76 APP (0.38) MAPTNPSR1TSHRGRM4
SCHEMBL254432 0.76 TRPV4 (0.53) GAANPC1ALDH1A1MAPTDYRK1A
SCHEMBL15087903 0.75 L3MBTL1 (0.45) NPC1ALDH1A1MAPTL3MBTL1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124309-A1 STAT6 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-05-07 US disclosed
US-12522619-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2026-01-13 US disclosed
US-20260008782-A1 HYDANTOIN MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION CONVELO THERAPEUTICS, INC. 2026-01-08 US disclosed
CN-119998288-A Hydantoin modulators of cholesterol biosynthesis and their use for promoting remyelination 基因泰克公司 2025-05-13 CN disclosed
WO-2025049820-A1 STAT6 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2025-03-06 WO disclosed
EP-4463462-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2024-11-20 EP disclosed
CN-118715231-A Complement factor inhibitors and uses thereof 安尼艾克松股份有限公司 2024-09-27 CN disclosed
WO-2024073658-A1 HYDANTOIN MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION GENENTECH, INC. (US) 2024-04-04 WO disclosed
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2023-08-24 US disclosed
WO-2023137166-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. (US) 2023-07-20 WO disclosed
EP-0708756-B1 SUBSTITUTED 2-PHENYLPYRIDINES WITH HERBICIDAL ACTION BASF AG (DE) 2005-06-01 EP disclosed
US-20040254159-A1 Heterocyclic kinase inhibitors ABBOTT LABORATORIES 2004-12-16 US disclosed
WO-2004076424-A1 HETEROCYCLIC KINASE INHIBITORS ABBOTT LABORATORIES (US) 2004-09-10 WO disclosed
US-20040162331-A1 Pyrrole derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2004-08-19 US disclosed
EP-1386913-A1 PYRROLE DERIVATIVE SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-02-04 EP disclosed
CN-1202159-A Pyrazin-2-one derivatives, their use, and intermediates for their production SUMITOMO CHEMICAL CO (JP) 1998-12-16 CN disclosed
US-5783522-A HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 1998-07-21 US disclosed
CN-1127504-A Substituted 2-phenylpyridines with herbicidal action BASF AG (DE) 1996-07-24 CN disclosed
EP-0708756-A1 SUBSTITUTED 2-PHENYLPYRIDINES WITH HERBICIDAL ACTION BASF AKTIENGESELLSCHAFT (DE) 1996-05-01 EP disclosed
WO-1995002580-A2 SUBSTITUTED 2-PHENYLPYRIDINES WITH HERBICIDAL ACTION BASF AKTIENGESELLSCHAFT (DE) 1995-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124309-A1 STAT6 DEGRADERS AND USES THEREOF STAT6, NCOR2, NCOR1 GAA 4235/4885NPC1 1390/4885ALDH1A1 2085/4885
US-20040254159-A1 Heterocyclic kinase inhibitors MAP3K20, MAP3K19, MAP3K1 GAA 2002/4885NPC1 3001/4885ALDH1A1 2391/4885
US-20260008782-A1 HYDANTOIN MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION SGMS1, MAG, SGMS2 GAA 3677/4885NPC1 5/4885ALDH1A1 1930/4885
US-20040162331-A1 Pyrrole derivative SLC5A1, GLP1R, SLC5A2 GAA 3027/4885NPC1 2030/4885ALDH1A1 548/4885
US-20230265109-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 GAA 233/4885NPC1 460/4885ALDH1A1 653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.